Trial Profile
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Oct 2023 Planned End Date changed from 1 Jul 2022 to 8 Aug 2024.
- 11 Oct 2023 Status changed from completed to active, no longer recruiting.
- 28 Jun 2023 Status changed from active, no longer recruiting to completed.